Highlight 2: esophageal and gastric cancer
Dr Eduard Callebout, working at UZ Gent, highlights key presentations from the session on oesophageal and stomach cancers at the 25th World Congress on Gastrointestinal Cancer in Barcelona. His video provides valuable insights into the latest developments in the field.
In his discussion, Dr Eduard Callebout highlights two significant studies in the neoadjuvant setting.
The first study is the INNOVATION study, also known as the EORTC-1203-GITCG study. This study draws parallels from the treatment of HER2-positive breast cancer and investigates the integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy for HER2-positive stomach cancer. The aim is to assess the potential benefits of these targeted therapies in improving outcomes for patients with HER2-positive stomach cancer.
The second study discussed by Dr Callebout is the EORTC-1707-GITCG study, commonly referred to as the VESTIGE-TRIAL. This study examines the potential advantages of adjuvant immunotherapy in patients who have undergone preoperative chemotherapy for gastric cancer and are identified as high-risk for relapse after surgical resection. The goal is to evaluate whether the addition of immunotherapy can provide further benefit in preventing disease recurrence.
Dr Callebout further discusses several studies focusing on the metastatic setting during his review.
The first study is the GEMSTONE-304 study, a Chinese trial that randomised patients with metastatic oesophageal squamous cell cancer in the first-line treatment. The study evaluated the addition of sugemalimab, an anti-PD-L1 antibody with retained antibody-dependent cellular phagocytosis activity, to standard chemotherapy regimens. The aim was to assess the efficacy and safety of this combination in improving outcomes for patients.
An update on the KEYNOTE-859 study is also covered in the review. This study investigates the potential benefits of adding pembrolizumab, an immune checkpoint inhibitor, to standard chemotherapy for patients with metastatic HER2-negative gastric or gastroesophageal junction cancer. The objective is to determine whether this combination therapy leads to improved outcomes compared to chemotherapy alone.
Dr Callebout also discusses a number of studies focusing on targeting fibroblast growth factor receptor (FGFR). One small study aims to evaluate the anti-tumour activity and safety of futibatinib in patients with gastric or gastroesophageal junction cancer harbouring a high-level FGFR2 amplification who have received at least two prior systemic regimens.
Furthermore, the phase II FIGHT study is also discussed, which included patients with gastric or gastroesophageal junction cancer harbouring an overexpression of FGFR2b and/or FGFR2 gene amplification. These patients were randomized to receive mFOLFOX6 chemotherapy with or without the addition of bemarituzumab, a targeted therapy directed against FGFR2b.
With the educational support of:
